COGT
Cogent Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$31.02Close
$5.0BMarket cap
$14.13 – $42.8452-week range
Nov 6, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Far from its high 28% below its 52-week high
- Results soon Nov 6, 2026, in 5 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
down 0.6%
price change
1mo
down 3.1%
price change
12-month return
up 91%
market up 11% ·
its own up 83%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.8×
price / book
Earnings yield
down 6.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 74%
return on equity
Free cash margin
—
-$266.0M FCF
D/E
0.35
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.1%
$1.28 a day · 2×ATR $28.47
RS
53 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
0.86
50 sessions
Implied move
—
no option chain · report Nov 6, 2026
Trend template · 1 of 8
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 45.7% over the year, from 110m to 161m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026-8% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.9M | — | — | — | — | — |
| Operating income | -$82.2M | -$75.6M | -$147.8M | -$208.1M | -$275.9M | -$333.4M |
| Net income | -$74.8M | -$72.3M | -$140.2M | -$192.4M | -$255.9M | -$328.9M |
| Net margin | -950% | — | — | — | — | — |
| Earnings per share | — | -$1.87 | -$2.39 | -$2.42 | -$2.46 | -$2.55 |
| Free cash flow | -$35.9M | -$60.5M | -$125.5M | -$156.4M | -$208.4M | -$266.0M |
| Free cash margin | -455% | — | — | — | — | — |
| Cash | $242.2M | $219.7M | $139.9M | $53.2M | $98.2M | $312.0M |
| Long-term debt | — | — | — | — | $0 | $222.9M |
| Shareholders' equity | $234.7M | $214.2M | $255.7M | $257.8M | $256.3M | $636.4M |
| Shares outstanding | 32.35m | 43.81m | 69.89m | 86.12m | 110.46m | 160.98m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 17, 2026 | Annual ↗ | Dec 31, 2025 | 48d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 2, 2026 | Material agreement ↗ |
| Aug 10, 2026 | Other events ↗ |
| Aug 10, 2026 | Results ↗ |
| Jun 11, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 17, 2026 | Results ↗ |
| Dec 8, 2025 | Other events ↗ |
| Nov 18, 2025 | Material agreement · New obligation ↗ |
| Nov 13, 2025 | Material agreement · Other events ↗ |
| Nov 10, 2025 | Regulation FD · Other events ↗ |
| Nov 3, 2025 | Results ↗ |
| Sep 11, 2025 | Material agreement · New obligation ↗ |